Cargando…
Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
BACKGROUND: Alzheimer’s disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized by progressive memory loss and gradual impairment of cognitive functions. Bapineuzumab is a fully humanized monoclonal antibody that binds to neurotoxic amyloid proteins in the brain, e...
Autores principales: | Abushouk, Abdelrahman Ibrahim, Elmaraezy, Ahmed, Aglan, Amro, Salama, Reham, Fouda, Samar, Fouda, Rana, AlSafadi, Ammar M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381133/ https://www.ncbi.nlm.nih.gov/pubmed/28376794 http://dx.doi.org/10.1186/s12883-017-0850-1 |
Ejemplares similares
-
Efficacy and safety of transcatheter aortic valve replacement in aortic stenosis patients at low to moderate surgical risk: a comprehensive meta-analysis
por: Elmaraezy, Ahmed, et al.
Publicado: (2017) -
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
por: Vandenberghe, Rik, et al.
Publicado: (2016) -
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015) -
Effect of metformin on maternal and neonatal outcomes in pregnant obese non-diabetic women: A meta-analysis
por: Elmaraezy, Ahmed, et al.
Publicado: (2017) -
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
por: Miles, Luke A., et al.
Publicado: (2013)